RESOURCE USE & COSTS

Patient characteristics¹

Age group	Females		Males		% females
Age group	Mean weight	SD	Mean weight	SD	% females
Adolescents aged 12-17 years	61 kg	22 kg	59 kg	17 kg	70.0
Adults aged 18-64 years	76 kg	18 kg	94 kg	20 kg	70.9
Adults aged 65 years and older	100 kg	40 kg	77 kg	6 kg	60.0

Consider drug wastage (ie, no vial sharing)

Prophylactic treatment

Treatment	Dosing		Administration	Unit Size	Pack Size	Cost per pack²	Cost per dose	Cost per year
Treatment	Units	Frequency	Administration	Unit Size	Pack Size	Cost per pack²	Cost per dose	Cost per year
TAKHZYRO³	300 mg	Every 14 days	SC May be self-administered	300 mg	1	$25,585	$25,585	$665,210
TAKHZYRO³	300 mg	Every 28 days	SC May be self-administered	300 mg	1	$25,585	$25,585	$332,605
CINRYZE⁴	1,000 IU	Every 3.5 days	IV May be self-administered	500 IU	1	$3,105	$6,210	$665,210
BERINERT⁵*	20 IU/kg	Every 3.5 days	IV May be self-administered	500 IU	1	$3,837	Variable per weight
HAEGARDA⁶	60 IU/kg	Every 3.5 days	SC May be self-administered	2000 IU	1	$2,200	Variable per weight
HAEGARDA⁶	60 IU/kg	Every 3.5 days	SC May be self-administered	3000 IU	1	$3,300	Variable per weight
ORLADEYO⁷	150 mg	Every 1.0 days	PO self-administered	150 mg	28	$42,366	$1,513.07	$552,271
ORLADEYO⁷	110 mg	Every 1.0 days	PO self-administered	110 mg	28	$42,366	$1,513.07	$552,271
Androgens⁸	200 mg	Every 1.0 days	PO self-administered	200 mg	100	$6.34	$6.34	$2,314
Placeholder	$0 per week							$0

*Indicated for both prophylactic and on-demand therapy, but not primarily used for prophylactic treatment.

VIEW VARIABLE DOSING DETAILS

On-demand treatment cost per HAE event

VIEW On-Demand DOSING, COSTS, AND MARKET SHARE DETAILS

References: 1. Data on file. HELP study: a multicenter, randomized, double-blind, placebo-controlled efficacy and safety study to evaluate DX-2930 for long-term prophylaxis against acute attacks of hereditary angioedema (HAE). (Clinical study report and patient level data, version 1) 2017. Shire, Inc. 2. IBM Micromedex. RED BOOK®. 2024. Accessed May 7, 2024. https://www.micromedexsolutions.com/home/dispatch/ssl/true 3. TAKHZYRO [prescribing information]. Lexington, MA: Takeda Pharmaceuticals U.S.A., Inc.; 2023. 4. CINRYZE [prescribing information]. Lexington, MA: Takeda Pharmaceuticals U.S.A., Inc.; 2023.5. BERINERT [prescribing information]. Kankakee, IL: CSL Behring LLC; 2021. 6. HAEGARDA [prescribing information]. Kankakee, IL: CSL Behring LLC; 2022. 7. ORLADEYO [prescribing information]. Durham, NC: BioCryst Pharmaceuticals, Inc.; 2023. 8. DANAZOL [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals; 2022. 9. FIRAZYR [prescribing information]. Lexington, MA: Takeda Pharmaceuticals U.S.A., Inc.; 2024. 10. RUCONEST [prescribing information]. Warren, NJ: Pharming Healthcare Inc.; 2020. 11. KALBITOR. [prescribing information]. Lexington, MA: Takeda Pharmaceuticals U.S.A., Inc.; 2021.

RESOURCE USE & COSTS

INDICATION

IMPORTANT SAFETY INFORMATION